Traumatic brain injury is one of the most common acquired causes of cognitive impairment across the lifespan, and a substantial minority of survivors meet DSM-5-TR criteria for a neurocognitive disorder weeks to years after the index event. The diagnosis sits within the DSM-5-TR neurocognitive disorders chapter as either major or mild Neurocognitive disorder due to traumatic brain injury, requiring evidence of impact from the injury and onset of cognitive deficits in the immediate post-injury period that persist past the acute recovery phase. Clinically, the picture is heterogeneous, blending executive dysfunction, slowed processing, attentional impairment, and a neuropsychiatric overlay of irritability, apathy, depression, and post-traumatic headache. Severity of the initial injury — graded by depth and duration of altered consciousness, post-traumatic amnesia, and structural imaging — is the strongest predictor of long-term cognitive outcome, but mild injuries can also produce persistent symptoms in a meaningful minority. Management is rehabilitative and symptom-targeted rather than disease-modifying; no agent has been shown to reverse the underlying neurocognitive disorder. The bottom line for the bedside is to confirm the injury, characterize the cognitive profile with neuropsychological testing, treat the neuropsychiatric overlay aggressively, and set realistic functional goals.

Traumatic brain injury is common, but the proportion who go on to meet criteria for a persistent neurocognitive disorder is much smaller — driven heavily by injury severity, age, and access to rehabilitation.

Incidence and burden

• Global age-standardized incidence of TBI is estimated at roughly 369 per 100,000 person-years, with about 27 million new cases annually.^[1]
• In the United States, TBI-related emergency department visits exceed 2.5 million per year, with hospitalizations near 282,000 and deaths near 56,000.^[2]
• Approximately 70 to 90 percent of TBIs are classified as mild on presentation, though mild does not preclude persistent cognitive symptoms.^[3]

Age and sex distribution

• Incidence shows a bimodal-to-trimodal age distribution with peaks in young children, adolescents and young adults, and adults over 75 years.^[1-2]
• Males have roughly twice the incidence of females across most age bands, though the gap narrows in older adults where falls dominate the mechanism.^[2]
• Falls are the leading mechanism in children under 5 and adults over 65; motor vehicle collisions, assaults, and sports/recreation dominate in adolescents and young adults.^[2]

Prevalence of persistent neurocognitive disorder

• After moderate-to-severe TBI, persistent cognitive impairment sufficient to meet criteria for major or mild neurocognitive disorder occurs in roughly 40 to 65 percent of survivors at one year, depending on cohort and assessment method.^[4]
• After mild TBI, an estimated 10 to 20 percent of patients report persistent cognitive or neuropsychiatric symptoms beyond three months, though only a subset meet formal NCD criteria.^[3,5]
• Repetitive head impact exposure (military blast, contact sports) confers additional risk for late-life neurodegenerative changes, including chronic traumatic encephalopathy neuropathologic change, identifiable only at autopsy.^[6]

Comorbidity

• Major depressive disorder occurs in approximately 30 to 50 percent of TBI survivors within the first year.^[7]
• Post-traumatic stress disorder is common after TBIs sustained in combat or assault, with rates of 15 to 35 percent in military cohorts.^[8]
• Substance use disorders, both pre- and post-injury, are substantially over-represented and worsen cognitive and functional outcomes.^[7]
• Suicide risk is increased roughly two- to threefold after TBI of any severity, with mild TBI also carrying elevated risk.^[9]

Risk factors for worse cognitive outcome

• Greater injury severity by Glasgow Coma Scale, duration of loss of consciousness, and length of post-traumatic amnesia.^[4]
• Older age at injury, lower premorbid cognitive reserve, and pre-existing psychiatric or substance use disorders.^[4,7]
• Repetitive injury, particularly when occurring before recovery from a prior event (second-impact considerations).^[6]

TBI produces a cascade of primary mechanical injury and secondary neurochemical, vascular, and inflammatory processes that together shape the cognitive phenotype. The injury is structural, biochemical, and dynamic, evolving over hours to years.

Primary injury mechanisms

• Focal contusions, classically over the orbitofrontal and anterior temporal cortices where the brain strikes the bony sphenoid ridge and inner skull surface during acceleration-deceleration.^[10]
• Diffuse axonal injury, produced by rotational and shear forces, particularly affecting the corpus callosum, dorsolateral midbrain, and subcortical white matter — a key driver of slowed processing speed.^[10-11]
• Subdural, epidural, intraparenchymal, and subarachnoid hemorrhage, each with distinct mass-effect and pressure consequences.^[10]

Secondary injury cascade

• Excitotoxic glutamate release with calcium influx, mitochondrial dysfunction, and oxidative stress in the minutes-to-hours window.^[11]
• Neuroinflammation with sustained microglial activation lasting months to years, contributing to chronic neurodegeneration.^[12]
• Disruption of the blood-brain barrier, cerebral edema, and impaired autoregulation, increasing vulnerability to secondary insults from hypoxia and hypotension.^[11]

Neurotransmitter and circuit consequences

• Dopaminergic dysfunction within mesocortical and nigrostriatal pathways underpins much of the post-TBI executive and attentional impairment, providing rationale for stimulant and dopaminergic trials.^[13]
• Cholinergic deficits from injury to the basal forebrain contribute to attention and memory deficits, paralleling Alzheimer disease in that respect.^[13]
• Disruption of the Default mode network and frontoparietal control networks correlates with cognitive complaints even when structural imaging is normal.^[14]

Imaging correlates

• Acute CT identifies hemorrhage, contusion, mass effect, and skull fracture and is the imaging modality of choice in the first 24 hours.^[10]
• MRI, including susceptibility-weighted imaging, detects microhemorrhages and contusions missed by CT and is more sensitive for diffuse axonal injury.^[10]
• Diffusion tensor imaging shows reduced white matter integrity in chronic TBI, correlating with executive dysfunction and processing speed deficits.^[11]
• FDG-PET may show hypometabolism in frontal and temporal regions in chronic moderate-to-severe TBI.^[14]

Genetic and host factors

• The APOE ε4 allele is associated with worse cognitive recovery and higher risk of late-life neurodegeneration after TBI.^[15]
• Premorbid cognitive reserve (education, occupational complexity) buffers post-injury cognitive expression.^[4]
• Repetitive injury increases risk for chronic traumatic encephalopathy neuropathologic change, characterized by perivascular tau deposition at sulcal depths.^[6]

The DSM-5-TR places this entity within the neurocognitive disorders chapter, with two severity tiers — major and mild — sharing a TBI-specific etiologic anchor. The criteria require both evidence of a TBI and a temporal link between the injury and the cognitive deficits.

DSM-5-TR core requirements

• Evidence of a traumatic brain injury, defined by impact to the head or rapid acceleration-deceleration with at least one of: loss of consciousness, post-traumatic amnesia, disorientation and confusion, or neurologic signs (e.g. positive imaging, new seizure, hemiparesis, visual field cut).^[16]
• The neurocognitive disorder presents immediately after the TBI or immediately after recovery of consciousness and persists past the acute post-injury period.^[16]
• For major NCD: significant cognitive decline from a prior level of performance in one or more domains, substantiated by concern and ideally documented by standardized testing, with interference in independence in everyday activities.^[16]
• For mild NCD: modest decline in one or more domains, ideally documented by testing, with preserved independence (though the patient may use compensatory strategies or require greater effort).^[16]
• Deficits do not occur exclusively during delirium and are not better explained by another mental disorder.^[16]

TBI severity grading (a host of overlapping systems are used; below is the most widely taught):

• Mild TBI: Glasgow Coma Scale 13 to 15, loss of consciousness less than 30 minutes, post-traumatic amnesia under 24 hours, and absence of structural lesions on imaging.^[17]
• Moderate TBI: Glasgow Coma Scale 9 to 12, loss of consciousness 30 minutes to 24 hours, or post-traumatic amnesia of 1 to 7 days.^[17]
• Severe TBI: Glasgow Coma Scale 3 to 8, loss of consciousness greater than 24 hours, or post-traumatic amnesia exceeding 7 days.^[17]

Specifiers and modifiers

• For major NCD, specify with or without behavioral disturbance (e.g. psychotic symptoms, mood disturbance, agitation, apathy).^[16,36]
• Specify current severity for major NCD: mild (instrumental ADLs affected), moderate (basic ADLs affected), or severe (fully dependent).^[16]
• Mild NCD has no severity specifier but the with/without behavioral disturbance modifier still applies.^[16]

ICD-11 placement

• ICD-11 codes the syndrome as mild or amnestic-confabulatory or dementia presentations associated with diseases classified elsewhere, cross-referenced to the underlying intracranial injury code.^[18]
• The ICD-11 framework emphasizes the etiologic code (the TBI) plus the cognitive syndrome code, rather than a single combined diagnosis as in DSM-5-TR.^[18]

The cognitive profile of TBI is dominated by attention, processing speed, and executive dysfunction, with a neuropsychiatric overlay that often drives functional impairment more than the cognitive deficits themselves.^[20]

Core cognitive domains affected

• Attention and processing speed are the most consistently impaired domains across injury severities, manifesting as distractibility, slowed reaction time, and difficulty with divided attention.^[20]
• Executive dysfunction includes impaired planning, set-shifting, working memory, and inhibitory control, often disproportionate to bedside cognitive screening scores.^[20]
• Memory impairment is typically encoding and retrieval-based rather than the rapid-forgetting profile of Alzheimer disease; recognition is relatively preserved.^[20]
• Anomic-type language deficits and slowed verbal fluency are common; frank aphasia is less typical except with focal left-hemisphere lesions.^[21]
• Visuospatial deficits occur with right-hemisphere or posterior contusions but are less prominent than frontal-executive findings.^[21]

Neuropsychiatric overlay

• Apathy is the single most common neuropsychiatric sequela of TBI, affecting up to 60 percent of moderate-to-severe survivors and easily mistaken for depression.^[22]
• Irritability, low frustration tolerance, and episodic aggression occur in 30 to 50 percent of moderate-to-severe TBI patients and are leading reasons for rehabilitation placement failure.^[22]
• Depression occurs in roughly 30 percent of survivors within the first year and is associated with worse cognitive and functional outcomes.^[23]
• Anxiety, post-traumatic stress disorder, and disinhibition (sexual, social, or financial) are well described, particularly with orbitofrontal injury.^[23]
• Psychosis is uncommon but recognized, with an estimated relative risk of 2 to 5 versus the general population, typically presenting years after the injury.^[24]

Course and prototypical presentation

• An acute phase (minutes to days) of altered consciousness and post-traumatic amnesia is followed by a subacute phase (weeks to months) of rapid recovery, then a chronic phase where deficits stabilize or progress slowly.^[20]
• Most spontaneous recovery occurs in the first 6 to 12 months; gains beyond 2 years are typically rehabilitation-driven rather than spontaneous.^[20]
• A prototypical moderate-TBI presentation 6 months post-injury: a previously employed adult who returns to work but cannot keep pace, fatigues by midday, becomes irritable, and reports word-finding difficulty and forgetfulness that bedside Mini-Mental State Examination scores miss.^[20]

Atypical presentations and red flags

• Persistent post-concussive symptoms after mild TBI — headache, dizziness, sleep disruption, cognitive complaints — overlapping heavily with depression, PTSD, and chronic pain, complicate attribution.^[25]
• Post-traumatic epilepsy occurs in 5 to 20 percent of moderate-to-severe TBI and can present as cognitive fluctuation, staring spells, or new behavioral changes.^[26]
• Delayed deterioration after a stable interval should prompt imaging for chronic subdural hematoma, hydrocephalus, or post-traumatic syringomyelia.^[19]
• Sleep-wake disturbance, including post-traumatic hypersomnia and circadian dysregulation, is present in over 50 percent and worsens cognition.^[27]

Distinguishing TBI-related cognitive impairment from its mimics is mostly a matter of temporal sequence and injury documentation, but several entities can coexist and confound the picture.^[28]

Psychiatric and functional mimics

• Major depressive disorder produces "pseudodementia" with prominent processing slowing, poor effort on testing, and reversible deficits; depression and TBI frequently coexist.^[23]
• PTSD shares attentional impairment, irritability, and sleep disturbance with TBI sequelae, especially in combat and motor-vehicle injury cohorts.^[29]
• Somatic symptom and functional neurological disorders may emerge after mild TBI, particularly in litigation or compensation contexts.^[25]
• Malingering and exaggeration of cognitive deficits must be considered when secondary gain is present; performance validity testing is the standard tool.^[30]

Other neurocognitive disorders

• Alzheimer disease classically presents with prominent episodic memory loss and rapid forgetting, contrasting with the executive-attentional profile of TBI.^[31]
• Frontotemporal neurocognitive disorder can mimic TBI's behavioral variant, but onset is insidious and there is no injury history.^[31]
• Vascular neurocognitive disorder may co-occur, particularly in older patients whose fall produced the TBI.^[31]
• Chronic traumatic encephalopathy is a tauopathy linked to repetitive head impacts and currently a neuropathologic diagnosis; clinical traumatic encephalopathy syndrome criteria exist but lack diagnostic validity for living patients.^[32]

Medical and neurologic mimics

• Post-traumatic epilepsy with subclinical seizures or postictal states.^[26]
• Chronic subdural hematoma, particularly in older adults on anticoagulation.^[19]
• Normal pressure hydrocephalus, classically triad of gait apraxia, urinary incontinence, and cognitive impairment.^[33]
• Endocrine sequelae of TBI: post-traumatic hypopituitarism (growth hormone deficiency, hypothyroidism, hypogonadism) affects up to 30 percent of moderate-to-severe survivors and can present as fatigue and cognitive slowing.^[34]
• Substance use disorders, especially alcohol, which both predispose to TBI and worsen its cognitive effects.^[28]

Assessment hinges on documenting the injury, characterizing the cognitive profile, and screening for the neuropsychiatric and somatic comorbidities that drive disability.^[38] A structured interview supplemented by collateral and validated instruments outperforms unstructured clinical impression for both diagnosis and disposition.^[39]

Mandatory history elements

• Mechanism, date, and witnessed details of the injury, including helmet use, blast exposure, and repeat injuries.^[38]
• Initial GCS if available, duration of loss of consciousness, and length of post-traumatic amnesia.^[39]
• Acute imaging findings and any neurosurgical intervention.^[40]
• Course of cognitive, behavioral, somatic, and sleep symptoms from injury to present.^[41]
• Premorbid cognitive baseline, education, occupational functioning, learning disability, and prior brain injuries.^[38]
• Psychiatric history with focus on depression, anxiety, PTSD, and substance use, all of which are highly comorbid.^[42]
• Pain inventory, particularly post-traumatic headache and cervical pain.^[43]
• Medication review for sedatives, anticholinergics, opioids, and benzodiazepines that worsen cognition.^[44]

Physical and neurologic exam

• Cranial nerve exam with attention to anosmia (olfactory nerve shearing) and oculomotor abnormalities.^[45]
• Motor exam for subtle hemiparesis, tone changes, and coordination.^[45]
• Vestibular and balance testing — vestibular dysfunction is a major contributor to persistent symptoms.^[46]
• Mental status exam emphasizing attention, working memory, processing speed, and executive function.^[38]

Bedside cognitive screening

• MoCA is preferred over the MMSE in TBI because it samples executive and attentional domains more heavily.^[47]
• The MoCA is acceptable for tracking but is not sufficient for diagnosis of mild NCD due to TBI on its own.^[47]

Formal neuropsychological testing

• Comprehensive testing is the standard for confirming the cognitive profile and characterizing severity, particularly in mild NCD or when litigation, return-to-work, or disability questions are in play.^[48]
• Core domains tested: processing speed, attention, working memory, learning and memory, executive function, language, visuospatial skills, and motor speed.^[48]
• Performance validity tests (e.g. TOMM) are routinely embedded to detect suboptimal effort, which is common in compensation-seeking contexts.^[49]

Imaging

• Non-contrast head CT is the acute test of choice for ruling out hemorrhage and indicating neurosurgical lesions.^[50]
• MRI with susceptibility-weighted and FLAIR sequences is more sensitive for diffuse axonal injury, contusions, and microhemorrhages and is preferred for subacute and chronic evaluation.^[51]
• Advanced techniques (DTI, functional MRI, MR spectroscopy) remain research tools and are not required for diagnosis.^[52]
• Routine PET and SPECT are not recommended for clinical TBI diagnosis given variable findings and lack of established cutoffs.^[52]

Laboratory and electrophysiology

• Targeted workup to rule out reversible contributors: TSH, vitamin B12, electrolytes, glucose, and toxicology when relevant.^[53]
• Screen for post-traumatic hypopituitarism (cortisol, free T4, IGF-1, gonadotropins, prolactin) in moderate-to-severe TBI or when fatigue and cognitive symptoms are out of proportion — pituitary dysfunction is under-recognized.^[54]
• EEG is indicated when post-traumatic epilepsy is suspected; routine EEG is not part of the diagnostic workup.^[55]
• Blood-based biomarkers (GFAP, UCH-L1) are FDA-cleared for triage of mild TBI in the acute setting but do not establish or exclude chronic NCD.^[56]

Validated rating instruments

• Rivermead Post-Concussion Symptoms Questionnaire for symptom burden after mild TBI.^[57]
• Neurobehavioral Symptom Inventory used in VA settings for veteran populations.^[58]
• PHQ-9 and GAD-7 for routine depression and anxiety screening.^[59]
• PCL-5 when blast or assault mechanism raises PTSD suspicion.^[60]

What not to order

• Routine SPECT or qEEG for diagnosis of TBI-related NCD.^[52]
• Genetic testing or amyloid PET, except in carefully selected cases when late-life dementia comorbidity is suspected.^[61]
• Repeat CT scans in clinically stable patients without new findings.^[50]

Care of NCD due to TBI is rehabilitative, symptom-targeted, and interdisciplinary. No pharmacologic agent has been shown to reverse the underlying neurocognitive disorder, so treatment focuses on cognitive rehabilitation and aggressive management of the neuropsychiatric, sleep, pain, and endocrine comorbidities that amplify disability.^[62,96] Match the intensity of intervention to severity, time since injury, and functional goals.^[63]

Pharmacotherapy

• No drug is FDA-approved to treat the cognitive impairment of TBI-related NCD.^[64]
• Methylphenidate is the most studied agent for post-TBI cognitive symptoms, with evidence suggesting modest improvement in processing speed and attention in moderate-to-severe injury; typical starting dose methylphenidate 5 mg PO BID titrated to effect.^[65]
• Amantadine accelerates recovery from disorders of consciousness in the early post-acute period after severe TBI and is sometimes used off-label for chronic apathy and executive symptoms.^[66,93]
• Cholinesterase inhibitors (donepezil, rivastigmine) have been studied for post-TBI cognitive symptoms with mixed and modest results; not first-line and not guideline-recommended for routine use.^[67]
• SSRIs are first-line for post-TBI depression and irritability; sertraline 25-200 mg PO QD is well studied in this population.^[68]
• Treat post-traumatic insomnia with sleep hygiene, cognitive behavioral therapy for insomnia, and, when pharmacotherapy is needed, low-dose trazodone or melatonin in preference to benzodiazepines and Z-drugs, which worsen cognition.^[69]
• Manage post-traumatic headache per primary headache phenotype; avoid medication overuse and limit opioids.^[70]
• Treat agitation with environmental measures first; for pharmacologic treatment, propranolol has the best evidence; antipsychotics carry sedation and seizure-threshold concerns and are reserved for severe agitation.^[71]
• Avoid or minimize benzodiazepines, anticholinergics, sedating antihistamines, and chronic opioids, all of which worsen cognition and slow recovery.^[44]

Psychotherapy and cognitive rehabilitation

• Cognitive rehabilitation therapy delivered by trained occupational therapists or neuropsychologists is the cornerstone of treatment for moderate-to-severe TBI and is endorsed by multiple guidelines.^[73]
• Components include attention training, metacognitive strategy training, external compensatory aids (calendars, smartphone reminders, checklists), and environmental modification.^[73]
• Cognitive behavioral therapy is effective for post-TBI depression, anxiety, and insomnia and should be adapted with shorter sessions, written summaries, and increased repetition.^[74]
• Family psychoeducation and caregiver support reduce caregiver burden and improve patient outcomes.^[75]
• Vocational rehabilitation improves return-to-work rates in moderate-to-severe TBI.^[76]

Neuromodulation

• Repetitive transcranial magnetic stimulation has been studied for post-TBI depression and cognitive symptoms with limited evidence of benefit; not standard of care.^[77]
• Transcranial direct current stimulation remains investigational in this population.^[77]
• Electroconvulsive therapy can be used safely for severe post-TBI depression refractory to pharmacotherapy when clinically indicated.^[78]

Adjunctive

• Treat post-traumatic hypopituitarism per endocrinology guidance; growth hormone and testosterone replacement may improve fatigue and quality of life in deficient patients.^[54]
• Screen and treat obstructive sleep apnea, which is over-represented after TBI and worsens cognition.^[79,99]
• Vestibular rehabilitation for persistent dizziness and disequilibrium.^[46]
• Counsel on alcohol abstinence — even moderate use slows recovery and worsens cognition.^[35,80]
• Address driving safety formally; many jurisdictions require physician reporting after moderate-to-severe TBI.^[81]

The table below summarizes the strongest available evidence by intervention. Certainty values follow GRADE conventions and reflect the central randomized trials and major guideline syntheses available in this population.^[62,73]

The harms picture in TBI-related NCD is dominated by polypharmacy, sedation, and the pharmacodynamic vulnerability of an injured brain.^[44] Most drugs studied in this population have small effect sizes, short follow-up, and heterogeneous samples, limiting the certainty of any single recommendation.^[62]

Common harms

• Sedation and worsened cognition from benzodiazepines, anticholinergics, sedating antihistamines, and gabapentinoids.^[44]
• Stimulant-related insomnia, appetite suppression, irritability, and tachycardia.^[65]
• SSRI-related GI upset, sexual dysfunction, and hyponatremia, particularly in older patients.^[68]
• Beta-blocker bradycardia and hypotension limiting propranolol use for agitation.^[71]

Serious or rare harms

• Lowered seizure threshold from many psychotropics, in a population with elevated baseline epilepsy risk.^[55,72]
• Antipsychotic-associated motor recovery impairment in animal and observational human data.^[72]
• Falls and fractures from sedating regimens in elderly TBI patients.^[44]
• Serotonin syndrome with combined serotonergic agents commonly prescribed for mood, pain, and migraine.^[68]

Monitoring and withdrawal

• Stimulants require cardiovascular monitoring and reassessment for sustained benefit.^[65]
• SSRIs require monitoring for hyponatremia and bleeding risk; abrupt discontinuation produces a discontinuation syndrome.^[68]
• Long-term opioid and benzodiazepine use should be tapered with caregiver support.^[44]

Evidence-base limitations

• Most trials are small, heterogeneous in injury severity, and limited to short-term outcomes.^[62]
• Subgroup data on women, older adults, and non-white populations are sparse.^[62]
• The boundary between persistent post-concussive symptoms and mild NCD due to TBI is operationally fuzzy and varies by classification system.^[15-16]
• Many published positive trials have not been replicated, and publication bias is likely.^[62]

TBI cuts across age groups but its consequences and management differ substantially in pediatric, geriatric, perinatal, and military or contact-sport populations.^[3,82]

Pediatric

• Children and adolescents recover faster from a single uncomplicated mild TBI than adults but are vulnerable to disruption of developmental milestones in moderate-to-severe injury.^[83]
• Pediatric neuropsychological testing must be matched to developmental level, and school-based accommodations are central to management.^[83]
• Repeat injury before symptom resolution increases the risk of prolonged recovery and is the rationale for return-to-play protocols.^[84]

Geriatric

• Older adults are over-represented among severe TBI hospitalizations and have worse outcomes for any given injury severity.^[85]
• Falls are the dominant mechanism; concurrent anticoagulation is a major contributor to morbidity.^[85]
• TBI is an independent risk factor for incident dementia, though attributable risk for any individual is modest.^[86]

Perinatal

• Pregnancy itself is not a contraindication to standard TBI assessment or imaging; shield when possible.^[87]
• Choose psychotropics with the best perinatal safety record (e.g. sertraline for depression); engage psychiatry early.^[87]

Comorbid PTSD and substance use

• Mild TBI and PTSD frequently coexist in veterans and assault survivors; symptoms overlap and require integrated care.^[42,88]
• Alcohol use is over-represented as both cause and consequence of TBI; treat the substance use disorder concurrently.^[80]

Military and contact-sport athletes

• Blast and repetitive subconcussive exposure raise concern for CTE and other chronic neurodegenerative syndromes; clinical diagnosis is not yet established and surveillance follows expert consensus rather than validated criteria.^[37,89]

Outcome scales correlate with initial injury severity, age, and access to rehabilitation, but individual trajectories vary widely.^[90] Most patients with uncomplicated mild TBI return to baseline within weeks; a clinically significant minority do not.^[91]

Mild TBI

• Roughly 80-90 percent of adults recover symptomatically within three months; 10-20 percent develop persistent symptoms meeting criteria for mild NCD.^[91]
• Female sex, prior mental illness, prior TBI, and litigation context are associated with prolonged recovery.^[91]

Moderate-to-severe TBI

• Long-term cognitive impairment is the rule rather than the exception; functional recovery continues for years but plateaus in domains.^[92]
• The GOS-E is the standard outcome instrument for global functional outcome.^[3]
• Mortality is highest in the first year, with elevated long-term risk of suicide, accidental death, and seizures.^[9]

Late-life implications

• A history of moderate-to-severe TBI roughly doubles the risk of later dementia in epidemiologic cohorts; repeated mild TBI in athletes is associated with chronic traumatic encephalopathy at autopsy.^[37,86]

The emergencies in chronic TBI-related NCD are suicide, agitation, post-traumatic seizures, and undetected late deterioration.^[9,90] A low threshold for re-imaging and admission is appropriate when symptoms acutely worsen.^[90]

Suicide risk

• Standardized mortality ratios for suicide are roughly two to four times the general population after TBI of any severity.^[9]
• Screen at every visit; address access to firearms and means restriction explicitly.^[9]

Acute agitation

• Use environmental measures first — quiet room, familiar caregiver, reorientation.^[71]
• For pharmacologic control, prefer scheduled propranolol or short-term low-dose antipsychotics over benzodiazepines, which can paradoxically worsen agitation and impair recovery.^[71-72]

Late neurologic deterioration

• New or worsening headache, focal deficits, seizures, or rapid cognitive decline mandates re-imaging to evaluate for chronic subdural hematoma, hydrocephalus, or other delayed structural complications.^[90]
• Normal-pressure hydrocephalus after TBI presents with the classic triad of gait disturbance, urinary incontinence, and cognitive decline and is potentially reversible with shunting.^[3]

Hospitalization criteria

• Imminent suicide risk, severe agitation refractory to outpatient measures, status epilepticus, or new neurologic findings warrant admission.^[94-95]

TBI-related NCD sits at the intersection of psychiatry, neurology, rehabilitation medicine, and medicolegal practice, and several long-standing controversies shape clinical decisions.^[3]

Persistent post-concussive symptoms after mild TBI

• The relative contribution of injury-specific pathology versus expectation, attention to symptoms, comorbid PTSD and depression, litigation, and pre-existing vulnerability remains debated.^[97]
• Diagnostic labels (post-concussion syndrome, persistent post-concussive symptoms) vary across DSM-5-TR, ICD-11, and consensus definitions; ICD-11 retains a discrete post-concussional syndrome category that DSM-5-TR does not.^[98]

TBI and late-life neurodegeneration

• Moderate-to-severe TBI is associated with increased risk of later dementia, but the magnitude, dose-response, and mechanism remain uncertain.^[7]
• Whether repetitive mild head impacts cause CTE in a dose-dependent fashion, and what the in vivo diagnostic threshold should be, are areas of active research and contention.^[6]

Effort and validity testing

• Performance validity tests reliably detect suboptimal effort but their interpretation in patients with legitimate cognitive impairment, pain, and psychiatric comorbidity remains nuanced and contested in medicolegal settings.^[49]

Stimulants and amantadine

• Methylphenidate has reasonable evidence for processing speed and attention but is not guideline-endorsed as routine; clinicians vary widely in their threshold for use.^[65]
• Amantadine's role beyond the early post-acute disorder-of-consciousness window is supported mainly by small studies and expert opinion.^[66]

Hyperbaric oxygen and other emerging therapies

• Hyperbaric oxygen therapy has been heavily marketed for chronic TBI but high-quality trials have not shown benefit over sham; not recommended outside research.^[3]
• Stem cell therapy, nutraceuticals, and unregulated cognitive enhancers lack evidence and may cause harm.^[3]

Return to play and return to duty:

• Optimal timing of return to contact sport after concussion and return to military duty after blast exposure are areas of evolving consensus.^[100]

• DSM-5-TR neurocognitive disorder due to TBI requires evidence of head impact with loss of consciousness, post-traumatic amnesia, disorientation, or neurologic signs, and cognitive deficits beginning immediately after injury that persist past the acute period.^[1]
• Severity classification by initial injury: mild (LOC < 30 min, PTA < 24 h, GCS 13-15), moderate (LOC 30 min-24 h, PTA 1-7 d, GCS 9-12), severe (LOC > 24 h, PTA > 7 d, GCS 3-8).^[2]
• DSM-5-TR severity (major vs mild NCD) reflects current cognitive and functional impairment, not initial injury severity — a severe TBI may produce mild NCD years later, and a mild TBI rarely produces major NCD.^[1]
• Most common cognitive deficits after TBI are slowed processing speed, impaired attention, working memory deficits, and executive dysfunction; isolated amnestic presentations are atypical.^[20]
• The most consistent imaging finding in moderate-to-severe TBI is diffuse axonal injury on susceptibility-weighted MRI, often in corpus callosum and dorsolateral frontal white matter.^[12]
• Falls are the leading cause of TBI in older adults and young children; motor vehicle collisions and assaults predominate in young to middle-aged adults; blast is the signature mechanism of recent military conflicts.^[5]
• Apolipoprotein E ε4 may modestly worsen outcome after TBI but is not a clinical test for diagnosis or prognosis.^[16]
• Post-traumatic hypopituitarism is under-recognized and should be screened for in moderate-to-severe TBI with persistent fatigue or cognitive symptoms.^[54]
• MoCA is preferred over MMSE for TBI because it samples executive and attentional domains.^[47]
• Methylphenidate is the best-studied pharmacologic agent for post-TBI cognitive symptoms but is not FDA-approved for this indication.^[65]
• Avoid benzodiazepines, anticholinergics, sedating antihistamines, and chronic opioids in TBI patients; they worsen cognition and slow recovery.^[44]
• Cognitive rehabilitation therapy is the cornerstone of treatment for moderate-to-severe TBI and is guideline-endorsed.^[73]
• Suicide risk is approximately doubled after TBI and persists for years after injury.^[9]
• Chronic subdural hematoma is a critical reversible mimic of post-traumatic cognitive decline, particularly in older or anticoagulated patients.^[90]
• Chronic traumatic encephalopathy is a neuropathologic diagnosis confirmable only at autopsy; the validity of in vivo clinical criteria remains debated.^[6]

No external funding. No conflicts of interest declared. Peer-review status: pending.